Enhancing endothelial progenitor cell for clinical use

Circulating endothelial progenitor cells （EPCs） havebeen demonstrated to correlate negatively with vascularendothelial dysfunction and cardiovascular risk factors.However, translation of basic research into the clinicalpractice has been limited by the lack of unambiguousand consistent definitions of...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of stem cells Vol. 7; no. 6; pp. 894 - 898
Main Author Ye, Lei
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 26.07.2015
Subjects
and
CD34
Cell
cells
Clinical
Endothelial
function
number
progenitor
therapy;Enhancing
trials
Enhancing function and number
Clinical trials
Cell therapy
CD34
Endothelial progenitor cells
Online AccessGet full text

Cover

More Information
Summary:Circulating endothelial progenitor cells （EPCs） havebeen demonstrated to correlate negatively with vascularendothelial dysfunction and cardiovascular risk factors.However, translation of basic research into the clinicalpractice has been limited by the lack of unambiguousand consistent definitions of EPCs and reduced EPCcell number and function in subjects requiring them forclinical use. This article critically reviews the definitionof EPCs based on commonly used protocols, their valueas a biomarker of cardiovascular risk factor in subjectswith cardiovascular disease, and strategies to enhanceEPCs for treatment of ischemic diseases.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Telephone: +65-92373289 Fax: +65-68722998
Correspondence to: Kian-Keong Poh, MBBChir, FRCP, FACC, Associate Professor, Department of Cardiology, National University Heart Centre, National University Health System, 1E, Kent Ridge Road, NUHS Tower Block, Level 9, Singapore 119228, Singapore. kian_keong_poh@nuhs.edu.sg
Author contributions: Both authors contributed to this manuscript.
ISSN:1948-0210
1948-0210
DOI:10.4252/wjsc.v7.i6.894